ADB-BUTINACA
€ 63,80 – € 16.950,00Price range: € 63,80 through € 16.950,00
ADB-BUTINACA Powder is described as an indazole-3-carboxamide synthetic cannabinoid research material, also identified by the synonym ADMB-BINACA.
The supplied chemical name is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide.
The source describes a beige to off-white crystalline powder intended for controlled analytical and non-clinical laboratory investigation.
Relevant research contexts include chemical identity assessment, structural characterization, chromatographic comparison, and documentation of related indazole carboxamide compounds.
Chemical identity verification is required. The supplied molecular formula C19H28N4O2 and molecular weight 344.46 g/mol do not match the named structure, which corresponds to C18H26N4O2 and approximately 330.43 g/mol in its neutral form.
The actual chemical form, stereochemical composition, and CAS assignment have not been independently confirmed.
The source reports ingredient purity of at least 98%, third-party testing, batch traceability, and Certificates of Analysis.
No batch-specific analytical records were supplied to substantiate these claims.
The material is not established as a certified reference material or validated quantitative calibration standard.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
ADB-BUTINACA Powder – Indazole Carboxamide Research Material
ADB-BUTINACA Powder – Product Overview
ADB-BUTINACA Powder is the supplied catalog designation for a research material described as an indazole-3-carboxamide synthetic cannabinoid.
The source also identifies the compound by the alternative designation ADMB-BINACA.
The named chemical structure contains an N-butyl-substituted indazole ring system and a carboxamide-containing side chain.
The supplied product description identifies its physical presentation as beige to off-white crystalline powder.
The stated scientific contexts include chemical identification, structural characterization, chromatographic comparison, and documentation of related synthetic cannabinoid compounds.
These contexts describe possible areas of analytical investigation rather than demonstrated performance of the actual product batch.
The source describes the material as high purity and refers to independent analytical verification.
However, no actual Certificate of Analysis, reference spectrum, chromatogram, or batch record was provided.
An important discrepancy also exists between the source-provided molecular formula and the systematic chemical name.
This discrepancy must be resolved before definitive identity specifications are published.
The material is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product.
Chemical Identity & Classification
The supplied source identifies the compound as ADB-BUTINACA, also known as ADMB-BINACA.
The named compound belongs to the indazole-3-carboxamide family of synthetic cannabinoids.
The reported systematic name describes an indazole ring bearing a butyl substituent and a carboxamide-containing side chain. ADB-BUTINACA Powder
The supplied chemical information includes:
- Product designation: ADB-BUTINACA Powder
- Reported synonym: ADMB-BINACA
- Systematic chemical name: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide
- Chemical classification: Indazole-3-carboxamide synthetic cannabinoid
- CAS Registry Number: Source states unassigned; not independently verified
- Source-provided molecular formula: C19H28N4O2
- Source-provided molecular weight: 344.46 g/mol
- Formula corresponding to the named neutral structure: C18H26N4O2
- Calculated molecular weight for the named neutral structure: Approximately 330.43 g/mol
- Reported presentation: Crystalline powder
- Intended designation: Research Use Only
The source-provided molecular formula and molecular weight are mutually consistent.
However, they do not correspond to the named neutral chemical structure.
A molecular formula should not be treated as definitive unless it matches the verified structural identity and chemical form of the material.
The source does not establish whether the finished material is a neutral compound, salt, hydrate, or solvate.
The stereochemical composition is also not specified.
These details may affect definitive identification and interpretation of analytical data.
The claim that no CAS number has been assigned is not independently substantiated.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected record corresponds to the verified chemical structure and form.
Chemical & Physical Characteristics
The supplied source describes the product as beige to off-white crystalline powder.
No batch-specific physical inspection report, authenticated product image, or solid-state characterization record was supplied.
The reported appearance therefore remains a supplier-provided description.
The named structure contains an indazole ring system, an N-butyl substituent, and carboxamide functionality.
These structural features distinguish it from related indazole carboxamides containing different aromatic substitutions or side-chain arrangements.
The source describes the material as suitable for investigation of solubility and stability under analytical conditions.
However, no product-specific solubility measurements, thermal analysis records, or validated stability studies were supplied. ADB-BUTINACA Powder
The source does not establish a crystalline polymorph, particle-size distribution, hygroscopicity profile, or validated shelf life.
Because the supplied molecular formula conflicts with the systematic name, calculated or experimentally reported physicochemical properties should be associated with a confirmed structure.
The powder’s actual chemical composition and solid-state characteristics therefore remain subject to verification.
No definitive claims are made about analytical recovery, crystalline uniformity, or long-term physical stability.
Purity & Analytical Verification
The source claims typical ingredient purity of at least 98% by HPLC.
It also describes identity confirmation using mass spectrometry and NMR spectroscopy.
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed purity and analytical identity therefore remain unverified.
For ADB-BUTINACA Powder, resolving the chemical identity discrepancy is essential before interpreting any reported analytical findings. ADB-BUTINACA Powder
The source identifies LC-MS/MS, HPLC, UV analysis, and spectroscopic comparison as relevant analytical techniques.
However, no product-specific results were supplied demonstrating the identity, purity, or quantitative composition of the actual material.
The source also describes potential use in reference-standard preparation and method validation.
No certified reference-material documentation, assigned reference value, measurement-uncertainty statement, or metrological traceability record was provided.
The material should therefore not be described as a certified quantitative reference standard.
The source does not establish whether its purity claim refers to the named neutral structure, a different chemical form, or a particular batch.
Any definitive claims about purity, identity, impurity levels, or quantitative reference suitability require supporting analytical documentation.
Quality Control & Batch Integrity
The supplied source refers to third-party testing, batch-specific tracking, complete documentation, and controlled production conditions.
These are supplier-provided quality-assurance claims.
No independent laboratory report, manufacturing audit, batch record, or certification was supplied.
The claims therefore remain unverified.
Relevant documentation for a research chemical may include verified chemical identifiers, confirmed chemical form, stereochemical composition where applicable, batch number, analytical findings, receipt date, and available storage history.
The source does not establish independently verified purity, powder homogeneity, residual-solvent limits, or batch-to-batch equivalence.
For ADB-BUTINACA Powder, the distinction between source-reported specifications and verified analytical findings is especially important because the supplied identity information is inconsistent.
The Research Use Only designation describes intended positioning but does not independently demonstrate product quality, traceability, or validated analytical performance.
Claims concerning independent testing, manufacturing controls, impurity limits, and batch consistency should be supported by actual records. ADB-BUTINACA Powder
A Certificate of Analysis should be associated with the specific material and batch to which its findings apply.
Safety, Handling & Laboratory Precautions
ADB-BUTINACA is described as a synthetic cannabinoid belonging to the indazole-3-carboxamide family.
Compounds in this broader category may present serious toxicological hazards, including unpredictable neurological and cardiovascular effects.
The supplied source does not provide a complete product-specific toxicological assessment or verified Safety Data Sheet.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
Fine powders can introduce additional concerns involving accidental dispersal and unintended exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical identity, ingredient purity, and physical characteristics have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The source describes nominal 1 g analytical portions supplied in resealable, inert packaging.
No actual packaging specification, container-validation report, or shipment-condition record was supplied.
The source recommends storage at approximately -20°C in a dry environment protected from light and moisture. ADB-BUTINACA Powder
No validated product-specific stability study was supplied to establish that temperature as a verified requirement or to support a particular shelf life.
For ADB-BUTINACA Powder, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
The source does not establish validated long-term stability or preservation of crystalline characteristics under the suggested storage conditions.
No guarantee of stability or packaging performance is implied by the source-provided recommendations.
Intended Research Use & Market Positioning
The supplied scientific context places ADB-BUTINACA within analytical research involving indazole carboxamide chemical identity, structural characterization, and comparative synthetic cannabinoid profiling.
The named N-butyl-substituted indazole ring system and carboxamide-containing side chain provide distinguishing structural features relevant to chemical identification.
However, the source-provided molecular formula and molecular weight must be reconciled with the systematic chemical name.
The source describes interest in chromatographic characterization, spectroscopic identification, and analytical comparison with related compounds.
No product-specific analytical validation, certified reference-material documentation, or stability study was supplied.
The Raw Lab Chems catalog identifies ADB-BUTINACA Powder as the product listing discussed here.
For related catalog context, the supplied source also identifies 5BR-ADB-INACA Powder and 6-CL-ADBA.
These related listings represent separate chemical designations and should not be treated as chemically identical to ADB-BUTINACA. ADB-BUTINACA Powder
The supplied information does not establish equivalent chemical identity, purity, chemical form, or analytical performance across these products.
These catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The source describes international shipping, tracking, temperature-controlled transport, and supporting customs documentation.
No current inventory record, carrier agreement, temperature-validation report, shipment authorization, or verified delivery information was supplied.
The source also claims compliance with IATA and DOT requirements.
No applicable dangerous-goods classification, shipping declaration, or transport-compliance documentation was provided to substantiate those claims.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
Synthetic cannabinoids may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws. ADB-BUTINACA Powder
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
ADB-BUTINACA is described as an indazole-3-carboxamide synthetic cannabinoid.
Its possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction and confirmed chemical identity.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (grams) |
2 ,5 ,10 ,25 ,50 ,100 ,250 ,500 ,1000 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.